Last reviewed · How we verify
ABSK043 in combination with Glecirasib
ABSK043 in combination with Glecirasib is a Small molecule drug developed by Abbisko Therapeutics Co, Ltd. It is currently in Phase 2 development.
At a glance
| Generic name | ABSK043 in combination with Glecirasib |
|---|---|
| Sponsor | Abbisko Therapeutics Co, Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABSK043 in combination with Glecirasib CI brief — competitive landscape report
- ABSK043 in combination with Glecirasib updates RSS · CI watch RSS
- Abbisko Therapeutics Co, Ltd portfolio CI
Frequently asked questions about ABSK043 in combination with Glecirasib
What is ABSK043 in combination with Glecirasib?
ABSK043 in combination with Glecirasib is a Small molecule drug developed by Abbisko Therapeutics Co, Ltd.
Who makes ABSK043 in combination with Glecirasib?
ABSK043 in combination with Glecirasib is developed by Abbisko Therapeutics Co, Ltd (see full Abbisko Therapeutics Co, Ltd pipeline at /company/abbisko-therapeutics-co-ltd).
What development phase is ABSK043 in combination with Glecirasib in?
ABSK043 in combination with Glecirasib is in Phase 2.